Base de dados : MEDLINE
Pesquisa : D09.408.051.476.060 [Categoria DeCS]
Referências encontradas : 3819 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 382 ir para página                         

  1 / 3819 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29458544
[Au] Autor:Aguilar-Ayala DA; Cnockaert M; Vandamme P; Palomino JC; Martin A; Gonzalez-Y-Merchand J
[Ad] Endereço:2​Laboratory of Microbiology, Department of Biochemistry and Microbiology, Ghent University, Ghent 9000, Belgium.
[Ti] Título:Antimicrobial activity against Mycobacterium tuberculosis under in vitro lipid-rich dormancy conditions.
[So] Source:J Med Microbiol;67(3):282-285, 2018 Mar.
[Is] ISSN:1473-5644
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Although tuberculosis treatment is dependent on drug-susceptibility testing (DST) and molecular drug-resistance detection, treatment failure and relapse remain a challenge. This could be partially due to the emergence of antibiotic-tolerant dormant mycobacteria, where host lipids have been shown to play an important role. This study evaluated the susceptibility of Mycobacterium tuberculosis to two antibiotic combinations - rifampicin, moxifloxacin, amikacin and metronidazole (RIF-MXF-AMK-MTZ), and rifampicin, moxifloxacin, amikacin and pretomanid (RIF-MXF-AMK-PA) - in a lipid-rich dormancy model. Although their effectiveness in in vitro cultures with dextrose as a carbon source has been proved, we observed that none of the antibiotic mixtures were bactericidal in the presence of lipids. The presence of lipids may confer tolerance to M. tuberculosis against the mixture of antibiotics tested and such tolerance could be even higher during the dormant stages. The implementation of lipids in DST on clinical isolates could potentially lead to a better treatment strategy.
[Mh] Termos MeSH primário: Antibacterianos/farmacologia
Lipídeos/farmacologia
Mycobacterium tuberculosis/efeitos dos fármacos
Mycobacterium tuberculosis/fisiologia
[Mh] Termos MeSH secundário: Amicacina/farmacologia
Antituberculosos/farmacologia
Tolerância a Medicamentos
Fluoroquinolonas/farmacologia
Aptidão Genética
Genótipo
Seres Humanos
Metabolismo dos Lipídeos
Testes de Sensibilidade Microbiana
Modelos Biológicos
Infecções por Micobactéria não Tuberculosa/microbiologia
Mycobacterium tuberculosis/genética
Mycobacterium tuberculosis/crescimento & desenvolvimento
Nitroimidazóis/farmacologia
Rifampina/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (2-nitro-6-(4-(trifluoromethoxy)benzyloxy)-6,7-dihydro-5H-imidazo(2,1-b)(1,3)oxazine); 0 (Anti-Bacterial Agents); 0 (Antitubercular Agents); 0 (Fluoroquinolones); 0 (Lipids); 0 (Nitroimidazoles); 84319SGC3C (Amikacin); U188XYD42P (moxifloxacin); VJT6J7R4TR (Rifampin)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180221
[St] Status:MEDLINE
[do] DOI:10.1099/jmm.0.000681


  2 / 3819 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29422757
[Au] Autor:Varshney A; Das M; Chaudhary P; Kumari R; Yadav K
[Ad] Endereço:Department of Vitreoretina, C. L. Gupta Eye Institute, Moradabad, Uttar Pradesh, India.
[Ti] Título: as a Causative Agent for Postoperative Endophthalmitis.
[So] Source:Middle East Afr J Ophthalmol;24(4):213-215, 2017 Oct-Dec.
[Is] ISSN:0975-1599
[Cp] País de publicação:India
[La] Idioma:eng
[Ab] Resumo:We report a case of a 55-year-old female who presented with pain, redness, and profound visual loss in her right eye 2 weeks after cataract surgery. An ophthalmic examination showed light perception vision, corneal edema with severe anterior chamber reaction and hypopyon, exudative membranes on the anterior lens surface, and dense vitreous exudates. Under the impression of acute postoperative exogenous endophthalmitis, immediate pars plana vitrectomy with culture of vitreous aspirate and intravitreal antibiotic injections were performed. Bacterial growth was observed on culture plates and broths which were identified as by VITEK 2 compact system. So far, no report has been published regarding endophthalmitis due to . Here, we present the first report of isolated from the ocular specimen.
[Mh] Termos MeSH primário: Aeromonas salmonicida/isolamento & purificação
Endoftalmite/microbiologia
Infecções Oculares Bacterianas/microbiologia
Infecções por Bactérias Gram-Negativas/microbiologia
Complicações Pós-Operatórias
[Mh] Termos MeSH secundário: Amicacina/uso terapêutico
Antibacterianos/uso terapêutico
Extração de Catarata
Dexametasona/uso terapêutico
Quimioterapia Combinada
Endoftalmite/diagnóstico
Endoftalmite/tratamento farmacológico
Infecções Oculares Bacterianas/diagnóstico
Infecções Oculares Bacterianas/tratamento farmacológico
Feminino
Glucocorticoides/uso terapêutico
Infecções por Bactérias Gram-Negativas/diagnóstico
Infecções por Bactérias Gram-Negativas/tratamento farmacológico
Seres Humanos
Injeções Intravítreas
Implante de Lente Intraocular
Meia-Idade
Acuidade Visual/fisiologia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Glucocorticoids); 7S5I7G3JQL (Dexamethasone); 84319SGC3C (Amikacin)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180223
[Lr] Data última revisão:
180223
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180210
[St] Status:MEDLINE
[do] DOI:10.4103/meajo.MEAJO_238_17


  3 / 3819 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29390522
[Au] Autor:Ko J; Kim SK; Yong DE; Kim TI; Kim EK
[Ad] Endereço:Department of Ophthalmology, Corneal Dystrophy Research Institute, Institute of Vision Research, Yonsei University College of Medicine.
[Ti] Título:Delayed onset Mycobacterium intracellulare keratitis after laser in situ keratomileusis: A case report and literature review.
[So] Source:Medicine (Baltimore);96(51):e9356, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Infectious keratitis is a relatively uncommon but potentially sight-threatening complication of laser in situ keratomileusis (LASIK). Mycobacterial keratitis is usually regarded as late onset keratitis among post-LASIK keratitis. There has been no documented case of Mycobacterium intracellulare post-LASIK keratitis of a long-latent period. PATIENT CONCERNS: A 36-year-old man was referred to our out-patient clinic, for persistent corneal epithelial defect with intrastromal infiltration. He had undergone uneventful bilateral LASIK procedure 4 years before. He complained decreased vision, accompanied by ocular pain, photophobia, and redness in his left eye for 7 months. DIAGNOSIS: Lamellar keratectomy was taken using femtosecond laser. Bacterial culture with sequenced bacterial 16s ribosomal DNA confirmed the organism to be M intracellulare. INTERVENTIONS: After 3 months of administration of topical clarithromycin, amikacin, and moxifloxacin, the corneal epithelial defect was resolved and the infiltration was much improved. However, newly developed diffuse haziness with surrounding granular infiltration in the central cornea was noted. Drug toxicity was suspected and topical moxifloxacin was discontinued, resulting in resolution of the diffuse haze with infiltration. OUTCOME: The patient was followed up regularly without medication thereafter and recurrence was not found for 7 years. LESSONS: This case presents the first case of M intracellulare keratitis after LASIK. LASIK surgeons should aware that post-LASIK keratitis can develop long after the operation and careful suspicion of infectious disease with meticulous diagnostic test is needed.
[Mh] Termos MeSH primário: Antibacterianos/uso terapêutico
Infecções Oculares Bacterianas/diagnóstico
Ceratite/microbiologia
Ceratomileuse Assistida por Excimer Laser In Situ/efeitos adversos
Complexo Mycobacterium avium/isolamento & purificação
[Mh] Termos MeSH secundário: Administração Tópica
Adulto
Amicacina/uso terapêutico
Claritromicina/uso terapêutico
Quimioterapia Combinada
Infecções Oculares Bacterianas/tratamento farmacológico
Infecções Oculares Bacterianas/etiologia
Fluoroquinolonas/uso terapêutico
Seguimentos
Seres Humanos
Ceratite/tratamento farmacológico
Ceratite/etiologia
Ceratomileuse Assistida por Excimer Laser In Situ/métodos
Masculino
Índice de Gravidade de Doença
Resultado do Tratamento
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Fluoroquinolones); 84319SGC3C (Amikacin); H1250JIK0A (Clarithromycin); U188XYD42P (moxifloxacin)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180219
[Lr] Data última revisão:
180219
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180203
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009356


  4 / 3819 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29370234
[Au] Autor:Madhi F; Jung C; Timsit S; Levy C; Biscardi S; Lorrot M; Grimprel E; Hees L; Craiu I; Galerne A; Dubos F; Cixous E; Hentgen V; Béchet S; Bonacorsi S; Cohen R; Urinary-tract Infection due to Extended-Spectrum Beta-lactamase­producing Enterobacteriaceae in Children Group
[Ad] Endereço:Service de Pédiatrie Générale, Centre Hospitalier Intercommunal de Créteil, Créteil, France.
[Ti] Título:Febrile urinary-tract infection due to extended-spectrum beta-lactamase-producing Enterobacteriaceae in children: A French prospective multicenter study.
[So] Source:PLoS One;13(1):e0190910, 2018.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: To assess the management of febrile urinary-tract infection (FUTIs) due to extended-spectrum ß-lactamase-producing Enterobacteriaceae (ESBL-E) in children, the Pediatric Infectious Diseases Group of the French Pediatric Society set up an active surveillance network in pediatric centers across France in 2014. MATERIALS AND METHODS: We prospectively analysed data from 2014 to 2016 for all children < 18 years old who received antibiotic treatment for FUTI due to ESBL-E in 24 pediatric centers. Baseline demographic, clinical features, microbiological data and antimicrobials prescribed were collected. RESULTS: 301 children were enrolled in this study. The median age was 1 year (IQR 0.02-17.9) and 44.5% were male. These infections occurred in children with history of UTIs (27.3%) and urinary malformations (32.6%). Recent antibiotic use was the main associated factor for FUTIs due to ESBL-E, followed by a previous hospitalization and travel history. Before drug susceptibility testing (DST), third-generation cephalosporins (3GC) PO/IV were the most-prescribed antibiotics (75.5%). Only 13% and 24% of children received amikacine alone for empirical or definitive therapy, respectively, whereas 88.7% of children had isolates susceptible to amikacin. In all, 23.2% of children received carbapenems in empirical and/or definitive therapy. Cotrimoxazole (24.5%), ciprofloxacin (15.6%) and non-orthodox clavulanate-cefixime combination (31.3%) were the most frequently prescribed oral options after obtaining the DST. The time to apyrexia and length of hospital stay did not differ with or without effective empirical therapy. CONCLUSIONS: We believe that amikacin should increasingly take on a key role in the choice of definitive therapy of FUTI due to ESBL-E in children by avoiding the use of carbapenems.
[Mh] Termos MeSH primário: Infecções por Enterobacteriaceae/microbiologia
Enterobacteriaceae/enzimologia
Infecções Urinárias/microbiologia
beta-Lactamases/biossíntese
[Mh] Termos MeSH secundário: Adolescente
Amicacina/uso terapêutico
Antibacterianos/efeitos adversos
Antibacterianos/uso terapêutico
Carbapenêmicos/efeitos adversos
Criança
Pré-Escolar
Enterobacteriaceae/efeitos dos fármacos
Infecções por Enterobacteriaceae/tratamento farmacológico
Infecções por Enterobacteriaceae/epidemiologia
Feminino
Febre/tratamento farmacológico
Febre/microbiologia
França/epidemiologia
Seres Humanos
Lactente
Recém-Nascido
Masculino
Testes de Sensibilidade Microbiana
Estudos Prospectivos
Fatores de Risco
Infecções Urinárias/tratamento farmacológico
Infecções Urinárias/epidemiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY; OBSERVATIONAL STUDY
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Carbapenems); 84319SGC3C (Amikacin); EC 3.5.2.6 (beta-Lactamases)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180213
[Lr] Data última revisão:
180213
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180126
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0190910


  5 / 3819 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28460426
[Au] Autor:Schoonover MJ; Moser DK; Young JM; Payton ME; Holbrook TC
[Ad] Endereço:Department of Veterinary Clinical Sciences, Oklahoma State University, Stillwater, Oklahoma.
[Ti] Título:Effects of tourniquet number and exsanguination on amikacin concentrations in the radiocarpal and distal interphalangeal joints after low volume intravenous regional limb perfusion in horses.
[So] Source:Vet Surg;46(5):675-682, 2017 Jul.
[Is] ISSN:1532-950X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To determine the influence of a dual tourniquet technique and limb exsanguination on amikacin concentrations in the synovial fluid of the radiocarpal joint (RCJ) and distal interphalangeal joint (DIPJ) after low volume, cephalic intravenous regional limb perfusion (IVRLP). STUDY DESIGN: Randomized cross-over design. ANIMALS: Six healthy adult horses. METHODS: One gram of amikacin in 6 mL of 0.9% NaCl was infused via cephalic IVRLP in 6 standing, sedated horses using 4 techniques: proximal pneumatic tourniquet (P), proximal pneumatic tourniquet with exsanguination (PE), proximal pneumatic and distal Esmarch tourniquet (PD), and proximal pneumatic with distal Esmarch tourniquet and exsanguination (PDE). Amikacin concentrations were measured in RCJ and DIPJ synovial fluid samples, collected just before perfusion (time 0), and at 15 and 30 minutes (before tourniquet release) after perfusion. RESULTS: Synovial fluid amikacin concentrations achieved in the RCJ were higher with techniques PD and PDE than those achieved with techniques P and PE 15 and 30 minutes after perfusion (P < .0001). Synovial fluid amikacin concentrations in the DIPJ were higher with techniques P and PE than those achieved with techniques PD and PDE at 15 minutes (P = .0002) and were higher than technique PDE at 30 minutes after perfusion (P < .0001). CONCLUSION: Low volume (10 mL) cephalic IVRLP should be combined with the placement of 2 tourniquets (proximal and distal to the carpus) to achieve therapeutic amikacin concentrations in the RCJ. Exsanguination prior to low volume IVRLP does not alter synovial fluid amikacin concentrations.
[Mh] Termos MeSH primário: Amicacina/química
Amicacina/farmacocinética
Antibacterianos/farmacocinética
Cavalos
Líquido Sinovial/química
Torniquetes/veterinária
[Mh] Termos MeSH secundário: Amicacina/administração & dosagem
Animais
Antibacterianos/administração & dosagem
Estudos Cross-Over
Membro Anterior
Perfusão
Procedimentos Cirúrgicos Vasculares
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 84319SGC3C (Amikacin)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171128
[Lr] Data última revisão:
171128
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170502
[St] Status:MEDLINE
[do] DOI:10.1111/vsu.12662


  6 / 3819 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28988110
[Au] Autor:Fadel MA; El-Gebaly RH; Mohamed SA; Abdelbacki AMM
[Ad] Endereço:Biophysics Department, Faculty of Science, Cairo University, Egypt.
[Ti] Título:Biophysical control of the growth of Agrobacterium tumefaciens using extremely low frequency electromagnetic waves at resonance frequency.
[So] Source:Biochem Biophys Res Commun;494(1-2):365-371, 2017 Dec 09.
[Is] ISSN:1090-2104
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Isolated Agrobacterium tumefaciens was exposed to different extremely low frequencies of square amplitude modulated waves (QAMW) from two generators to determine the resonance frequency that causes growth inhibition. The carrier was 10 MHz sine wave with amplitude ±10 Vpp which was modulated by a second wave generator with a modulation depth of ± 2Vpp and constant field strength of 200 V/m at 28 °C. The exposure of A. tumefaciens to 1.0 Hz QAMW for 90 min inhibited the bacterial growth by 49.2%. In addition, the tested antibiotics became more effective against A. tumefaciens after the exposure. Furthermore, results of DNA, dielectric relaxation and TEM showed highly significant molecular and morphological changes due to the exposure to 1.0 Hz QAMW for 90 min. An in-vivo study has been carried out on healthy tomato plants to test the pathogenicity of A. tumefaciens before and after the exposure to QAMW at the inhibiting frequency. Symptoms of crown gall and all pathological symptoms were more aggressive in tomato plants treated with non-exposed bacteria, comparing with those treated with exposed bacteria. We concluded that, the exposure of A. tumefaciens to 1.0 Hz QAMW for 90 min modified its cellular activity and DNA structure, which inhibited the growth and affected the microbe pathogenicity.
[Mh] Termos MeSH primário: Agrobacterium tumefaciens/efeitos da radiação
Antibacterianos/farmacologia
DNA Bacteriano/efeitos da radiação
Radiação Eletromagnética
[Mh] Termos MeSH secundário: Agrobacterium tumefaciens/efeitos dos fármacos
Agrobacterium tumefaciens/genética
Agrobacterium tumefaciens/crescimento & desenvolvimento
Amicacina/farmacologia
Carbenicilina/farmacologia
Cefaclor/farmacologia
Cloranfenicol/farmacologia
Ciprofloxacino/farmacologia
DNA Bacteriano/efeitos dos fármacos
Fluoroquinolonas/farmacologia
Gentamicinas/farmacologia
Lycopersicon esculentum/microbiologia
Tumores de Planta/microbiologia
Rifampina/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (DNA, Bacterial); 0 (Fluoroquinolones); 0 (Gentamicins); 5E8K9I0O4U (Ciprofloxacin); 66974FR9Q1 (Chloramphenicol); 69K7K19H4L (Cefaclor); 84319SGC3C (Amikacin); G42ZU72N5G (Carbenicillin); L4618BD7KJ (gatifloxacin); VJT6J7R4TR (Rifampin)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171108
[Lr] Data última revisão:
171108
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171009
[St] Status:MEDLINE


  7 / 3819 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28893358
[Au] Autor:Ko JH; Baek JY; Peck KR; Cho SY; Ha YE; Kim SH; Huh HJ; Lee NY; Kang CI; Chung DR; Song JH
[Ad] Endereço:1​Division of Infectious Diseases, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Republic of Korea.
[Ti] Título:Discrepant susceptibility to gentamicin despite amikacin resistance in Klebsiella pneumoniae by VITEK 2 represents false susceptibility associated with the armA 16S rRNA methylase gene.
[So] Source:J Med Microbiol;66(10):1448-1450, 2017 Oct.
[Is] ISSN:1473-5644
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Because we experienced gentamicin failure in Klebsiella pneumoniae bacteraemia that was susceptible to gentamicin despite amikacin resistance, as determined by VITEK 2, we evaluated the true susceptibility and mechanism of resistance. We screened 2818 K. pneumoniae isolates during a 1-year period at a university hospital and reviewed anti-microbial susceptibility reports using the VITEK 2 system. The minimum inhibitory concentration was substantiated by broth microdilution (BMD), and the presence of 16S rRNA methylase genes and aminoglycoside-modifying enzymes was also investigated. A total of 131 amikacin-resistant isolates from 19 patients were gentamicin non-resistant according to the VITEK 2 system. Among these, we were able to collect isolates from 12 patients (63.2 %), and a single isolate from each patient was tested. Eleven of the gentamicin non-resistant isolates (91.7 %) showed high-level resistance to both amikacin and gentamicin by BMD in association with the armA gene. Gentamicin is not an adequate treatment option for amikacin-resistant K. pneumoniae, even if VITEK 2 reports susceptibility.
[Mh] Termos MeSH primário: Amicacina/farmacologia
Antibacterianos/farmacologia
Gentamicinas/farmacologia
Klebsiella pneumoniae/efeitos dos fármacos
Metiltransferases/metabolismo
[Mh] Termos MeSH secundário: Farmacorresistência Bacteriana Múltipla
Regulação Bacteriana da Expressão Gênica
Regulação Enzimológica da Expressão Gênica
Metiltransferases/genética
Testes de Sensibilidade Microbiana/métodos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Gentamicins); 84319SGC3C (Amikacin); EC 2.1.1.- (Methyltransferases)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171018
[Lr] Data última revisão:
171018
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170913
[St] Status:MEDLINE
[do] DOI:10.1099/jmm.0.000583


  8 / 3819 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28719270
[Au] Autor:Bitan O; Wiener-Well Y; Segal R; Schwartz E
[Ad] Endereço:Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
[Ti] Título:Mycetoma (Madura Foot) in Israel: Recent Cases and a Systematic Review of the Literature.
[So] Source:Am J Trop Med Hyg;96(6):1355-1361, 2017 Jun.
[Is] ISSN:1476-1645
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:AbstractMycetoma is a chronic soft tissue infection caused by fungal or bacterial pathogens, and is endemic in tropical and subtropical regions. Cases in developed countries outside the mycetoma belt are rare and usually imported by immigrants. Sporadic cases have been reported in Israel. Unpublished cases in the participating medical centers are reported. In addition, a systematic review of the literature was performed. All published mycetoma cases diagnosed in Israel were included with relevant variables collected. Twenty-one cases of mycetoma were diagnosed in Israel between 1942 and 2015, including four unpublished cases and 17 published cases. The mean age at diagnosis was 42 years (range 23-73), and 16 of the patients were male. The foot was the primary involved organ. Fifteen patients were immigrants from Yemen, Ethiopia, and Sudan. Five cases were autochthonous. One case was travel related. Among patients who developed symptoms after immigration, the mean time from exposure to symptom onset was 5.6 years (range 1-10 years). The mean time from symptom onset to diagnosis was 6.6 years (range 0.2-35 years). The autochthonous cases demonstrate that Israel is endemic of mycetoma. The immigrant population represents two distinct waves of immigration to Israel in the past century. Two unpublished cases of Ethiopian immigrants are the first reported cases of mycetoma acquired in Ethiopia. The diagnostic and therapeutic challenges along with the epidemiological data emphasize the need of raising the awareness of physicians to this devastating condition even in developed countries.
[Mh] Termos MeSH primário: Emigrantes e Imigrantes
Micetoma/diagnóstico
Micetoma/etnologia
[Mh] Termos MeSH secundário: Adulto
Amicacina/uso terapêutico
Anti-Infecciosos/uso terapêutico
Bases de Dados Factuais
Etiópia/etnologia
Feminino
Seguimentos
Seres Humanos
Israel/epidemiologia
Masculino
Meia-Idade
Micetoma/tratamento farmacológico
Rifampina/uso terapêutico
Sudão/etnologia
Sulfametoxazol/uso terapêutico
Resultado do Tratamento
Trimetoprima/uso terapêutico
Iêmen/etnologia
Adulto Jovem
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Anti-Infective Agents); 84319SGC3C (Amikacin); AN164J8Y0X (Trimethoprim); JE42381TNV (Sulfamethoxazole); VJT6J7R4TR (Rifampin)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170823
[Lr] Data última revisão:
170823
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170719
[St] Status:MEDLINE
[do] DOI:10.4269/ajtmh.16-0710


  9 / 3819 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28716109
[Au] Autor:Kim HS; Park BK; Kim SK; Han SB; Lee JW; Lee DG; Chung NG; Cho B; Jeong DC; Kang JH
[Ad] Endereço:Department of Pediatrics, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul, 06591, Republic of Korea.
[Ti] Título:Clinical characteristics and outcomes of Pseudomonas aeruginosa bacteremia in febrile neutropenic children and adolescents with the impact of antibiotic resistance: a retrospective study.
[So] Source:BMC Infect Dis;17(1):500, 2017 Jul 17.
[Is] ISSN:1471-2334
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Although the proportion of Pseudomonas aeruginosa infections has reduced after the introduction of antibiotics with anti-pseudomonal effects, P. aeruginosa bacteremia still causes high mortality in immunocompromised patients. This study determined the clinical characteristics and outcomes of P. aeruginosa bacteremia and the antibiotic susceptibilities of strains isolated from febrile neutropenic patients. METHODS: Thirty-one febrile neutropenic children and adolescents with underlying hematologic/oncologic disorders diagnosed with P. aeruginosa bacteremia between 2011 and 2016 were enrolled in the study. Their medical records were retrospectively reviewed to evaluate the demographic and clinical characteristics. Antibiotic susceptibility rates of the isolated P. aeruginosa to eight antibiotic categories (anti-pseudomonal penicillin, anti-pseudomonal penicillin and ß-lactamase inhibitor combination, anti-pseudomonal cephalosporin, monobactam, carbapenem, aminoglycoside, fluoroquinolone, and colistin) were also determined. Among the investigated factors, risk factors for mortality and infections by a multidrug-resistance (MDR) strain were determined. RESULTS: Thirty-six episodes of P. aeruginosa bacteremia were identified. The mean age of the enrolled patients was 9.5 ± 5.4 years, and 26 (72.2%) episodes occurred in boys. Acute myeloid leukemia (41.7%) and acute lymphoblastic leukemia (33.3%) were the most common underlying disorders. The 30-day mortality was 38.9%, and 36.1% of the episodes were caused by MDR strains. The deceased patients were more likely to experience breakthrough infection (P = 0.036) and bacteremia (P = 0.005) due to MDR strains when compared with the patients who survived. The survived patients more likely received appropriate empirical antibiotic therapy (P = 0.024) and anti-pseudomonal ß-lactam and aminoglycoside combination therapy (P = 0.039) compared with the deceased patients. The antibiotic susceptibility rates of the isolated P. aeruginosa strains were as follows: piperacillin/tazobactam, 67.6%; meropenem, 72.2%; and amikacin, 100%. CONCLUSIONS: Mortality due to P. aeruginosa bacteremia remained at 38.9% in this study, and more than one-third of the isolated strains were MDR. In this context, empirical antibiotic combination therapy to expand the antibiotic spectrum may be a strategy to reduce mortality due to P. aeruginosa bacteremia in febrile neutropenic patients.
[Mh] Termos MeSH primário: Antibacterianos/uso terapêutico
Bacteriemia/microbiologia
Infecções por Pseudomonas/tratamento farmacológico
Infecções por Pseudomonas/etiologia
Pseudomonas aeruginosa/efeitos dos fármacos
[Mh] Termos MeSH secundário: Adolescente
Amicacina/farmacologia
Amicacina/uso terapêutico
Aminoglicosídeos/uso terapêutico
Bacteriemia/tratamento farmacológico
Bacteriemia/mortalidade
Carbapenêmicos/farmacologia
Carbapenêmicos/uso terapêutico
Cefalosporinas/farmacologia
Criança
Pré-Escolar
Farmacorresistência Bacteriana Múltipla/efeitos dos fármacos
Feminino
Febre/tratamento farmacológico
Fluoroquinolonas/farmacologia
Fluoroquinolonas/uso terapêutico
Seres Humanos
Masculino
Neutropenia/tratamento farmacológico
Neutropenia/microbiologia
Ácido Penicilânico/análogos & derivados
Ácido Penicilânico/uso terapêutico
Piperacilina/uso terapêutico
Infecções por Pseudomonas/mortalidade
Estudos Retrospectivos
Tienamicinas/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Aminoglycosides); 0 (Anti-Bacterial Agents); 0 (Carbapenems); 0 (Cephalosporins); 0 (Fluoroquinolones); 0 (Thienamycins); 157044-21-8 (piperacillin, tazobactam drug combination); 84319SGC3C (Amikacin); 87-53-6 (Penicillanic Acid); FV9J3JU8B1 (meropenem); X00B0D5O0E (Piperacillin)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171010
[Lr] Data última revisão:
171010
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170719
[St] Status:MEDLINE
[do] DOI:10.1186/s12879-017-2597-0


  10 / 3819 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28686663
[Au] Autor:Knafl D; Thalhammer F; Vossen MG
[Ad] Endereço:Division of Infectious Diseases and Tropical Medicine, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
[Ti] Título:In-vitro release pharmacokinetics of amikacin, teicoplanin and polyhexanide in a platelet rich fibrin-layer (PRF)-a laboratory evaluation of a modern, autologous wound treatment.
[So] Source:PLoS One;12(7):e0181090, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: Platelet rich fibrin (PRF) is an autologous fibrin glue, produced from patients' blood, which, besides intraoperative use, has applications in the treatment of infected wounds. The combination with antimicrobial agents results in a prolonged antibacterial effect allowing for wound dressing change intervals of seven days even in infected wounds. The aim of this study was to evaluate release kinetics of amikacin, teicoplanin or polyhexanide from a PRF-layer. METHODS: PRF mixed with teicoplanin, amikacin or polyhexanide was sprayed on a silicon gauze patch and put on a colombia agar with bacteria with known minimal inhibitory concentration (MIC) and incubated for 24 hours and afterwards transferred to another agar with the same bacterial strain. Inhibition zones were measured every 24 hours. This was repeated on 7 consecutive days. Antibiotic concentrations were calculated by interpolation. RESULTS: More than 1000 mg/L teicoplanin were released within the first 24 hours and 28.22 mg/L after 168 hours. Amikacin release was above 10,000 mg/L within the first 24 hours and still 120.8 mg/L after 120 hours. A release of polyhexanide could be verified for the first 24 hours only. Consequently teicoplanin and amikacin released from PRF showed antimicrobial in-vitro effects for almost a week, whereas an antimicrobial effect of polyhexanide could only be verified for the first 24 hours. CONCLUSIONS: Our Results show that a weekly dressing regimen may be justified in wounds treated with PRF plus amikacin or teicoplanin, since bacteria will be eradicated over a considerable period of time after a single application of PRF.
[Mh] Termos MeSH primário: Amicacina/farmacocinética
Antibacterianos/farmacocinética
Biguanidas/farmacocinética
Preparações de Ação Retardada/farmacocinética
Fibrina/farmacologia
Teicoplanina/farmacocinética
[Mh] Termos MeSH secundário: Ágar/química
Amicacina/farmacologia
Antibacterianos/farmacologia
Bandagens
Biguanidas/farmacologia
Preparações de Ação Retardada/farmacologia
Testes de Sensibilidade a Antimicrobianos por Disco-Difusão
Liberação Controlada de Fármacos
Seres Humanos
Klebsiella pneumoniae/efeitos dos fármacos
Klebsiella pneumoniae/crescimento & desenvolvimento
Staphylococcus aureus Resistente à Meticilina/efeitos dos fármacos
Staphylococcus aureus Resistente à Meticilina/crescimento & desenvolvimento
Modelos Biológicos
Fator de Crescimento Derivado de Plaquetas/farmacologia
Plasma Rico em Plaquetas/química
Pseudomonas aeruginosa/efeitos dos fármacos
Pseudomonas aeruginosa/crescimento & desenvolvimento
Teicoplanina/farmacologia
Cicatrização/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Biguanides); 0 (Delayed-Action Preparations); 0 (Platelet-Derived Growth Factor); 322U039GMF (polihexanide); 61036-62-2 (Teicoplanin); 84319SGC3C (Amikacin); 9001-31-4 (Fibrin); 9002-18-0 (Agar)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170922
[Lr] Data última revisão:
170922
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170708
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0181090



página 1 de 382 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde